High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based β-arrestin2 recruitment assay

Journal of Biomolecular Screening

Volumn 10, Issue 5, 2005, Pages 463-475

  Hamdan, Fadi F ^a   Audet, Martin ^a   Garneau, Philippe ^b   Pelletier, Jerry ^b   Bouvier, Michel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

BRET; CCR5; Fluorescence reporter assay; GPCR; High throughput screening; Luciferase reporter assay; arrestin

Indexed keywords

ARGIPRESSIN; BETA ARRESTIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR ANTAGONIST; ISOPRENALINE; LUCIFERASE; PINDOLOL; RANTES; RECEPTOR BLOCKING AGENT; STROMAL CELL DERIVED FACTOR 1ALPHA; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL STRAIN HEK293; HIGH THROUGHPUT SCREENING; MAMMAL CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

MAMMALIA; RENILLA LUCIFERASE;

EID: 24144488192     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057105275344     Document Type: Article

References (58)

1. Vassilatis DK, Hohmann JG, Zeng H, Li F, Ranchalis JE, Mortrud MT, et al: The G protein-coupled receptor repertoires of human and mouse. Proc Natl Acad Sci U S A 2003;100:4903-4908.
2. Spiegel AM: Defects in G protein-coupled signal transduction in human disease. Annu Rev Physiol 1996;58:143-170.
3. Wise A, Gearing K, Rees S: Target validation of G-protein coupled receptors. Drug Discov Today 2002;7:235-246.
4. Bockaert J, Fagni L, Dumuis A, Marin P: GPCR interacting proteins (GIP). Pharmacol Ther 2004;103:203-221.
5. Gurevich VV, Gurevich EV: The molecular acrobatics of arrestin activation. Trends Pharmacol Sci 2004;25:105-111.
6. Shenoy SK, Lefkowitz RJ: Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 2003;375:503-515.
7. Scott MG, Benmerah A, Muntaner O, Marullo S: Recruitment of activated G protein-coupled receptors to pre-existing clathrin-coated pits in living cells. J Biol Chem 2002;277:3552-3559.
8. Takei K, Haucke V: Clathrin-mediated endocytosis: membrane factors pull the trigger. Trends Cell Biol 2001;11:385-391.
9. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG: Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 1999;274:32248-32257.
10. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS: Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 2000;275:17201-17210.
11. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG: Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis. J Biol Chem 2001;276:19452-19460.
12. DeGraff JL, Gurevich W, Benovic JL: The third intracellular loop of alpha 2-adrenergic receptors determines subtype specificity of arrestin interaction. J Biol Chem 2002;277:43247-43252.
13. Huttenrauch F, Nitzki A, Lin FT, Honing S, Oppermann M: Beta-arrestin binding to CC chemokine receptor 5 requires multiple C-terminal receptor phosphorylation sites and involves a conserved Asp-Arg-Tyr sequence motif. J Biol Chem 2002;277:30769-30777.
14. Xu Y, Piston DW, Johnson CH: A bioluminescence resonance energy transfer (BRET) system: application to interacting circadian clock proteins. Proc Natl Acad Sci U S A 1999;96:151-156.
15. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, et al: Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci U S A 2000;97:3684-3689.
16. Heding A: Use of the BRET 7TM receptor/beta-arrestin assay in drug discovery and screening. Expert Rev Mol Diagn 2004;4:403-411.
17. Van Koppen CJ, Jakobs KH: Arrestin-independent internalization of G protein-coupled receptors. Mol Pharmacol 2004;66:365-367.
18. Breit A, Lagace M, Bouvier M: Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. J Biol Chem 2004;279:28756-28765.
19. Perroy J, Adam L, Qanbar R, Chenier S, Bouvier M: Phosphorylation- independent desensitization of GABA(B) receptor by GRK4. EMBO J 2003;22:3816-3824.
20. Milligan G: Applications of bioluminescence- and fluorescence resonance energy transfer to drug discovery at G protein-coupled receptors. Eur J Pharm Sci 2004;21:397-405.
21. Pfleger KD, Eidne KA: Monitoring the formation of dynamic G-protein coupled receptor/protein complexes in living cells. Biochem J 2005;385:625-637.
22. Berglund MM, Schober DA, Statnick MA, McDonald PH, Gehlert DR: The use of bioluminescence resonance energy transfer 2 to study neuropeptide Y receptor agonist-induced beta-arrestin 2 interaction. J Pharmacol Exp Ther 2003;306:147-156.
23. Kroeger KM, Hanyaloglu AC, Seeber RM, Miles LE, Eidne KA: Constitutive and agonist-dependent homo-oligomerization of the thyrotropin-releasing hormone receptor: detection in living cells using bioluminescence resonance energy transfer. J Biol Chem 2001;276:12736-12743.
24. Hansen JL, Theilade J, Haunso S, Sheikh SP: Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling but not ERK activation. J Biol Chem 2004;279:24108-24115.
25. Bertrand L, Parent S, Caron M, Legault M, Joly E, Angers S, et al: The BRET2/arrestin assay in stable recombinant cells: a platform to screen for compounds that interact with G protein-coupled receptors (GPCRS). J Recept Signal Transduct Res 2002;22:533-541.
26. Hanyaloglu AC, Seeber RM, Kohout TA, Lefkowitz RJ, Eidne KA: Homo- and hetero-oligomerization of thyrotropin-releasing hormone (TRH) receptor subtypes: differential regulation of beta-arrestins 1 and 2. J Biol Chem 2002;277:50422-50430.
27. Hasbi A, Devost D, Laporte SA, Zingg HH: Real-time detection of interactions between the human oxytocin receptor and G protein-coupled receptor kinase-2. Mol Endocrinol 2004;18:1277-1286.
28. Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, et al: Oxytocin and vasopressin Via and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol Endocrinol 2003;17:677-691.
29. Charest PG, Bouvier M: Palmitoylation of the V2 vasopressin receptor carboxyl tail enhances beta-arrestin recruitment leading to efficient receptor endocytosis and ERK1/2 activation. J Biol Chem 2003;278:41541-41551.
30. Berger EA, Murphy PM, Farber JM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
31. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A: A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 2002;20:87-90.
32. Donzella GA, Schols D, Lin SW, Este JA, Nagashima KA, Maddon PJ, et al: AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-77.
33. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, et al: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999;96:5698-5703.
34. Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, et al: Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist. J Clin Invest 1996;98:2729-2738.
35. Howl J, Wang X, Kirk CJ, Wheatley M: Fluorescent and biotinylated linear peptides as selective bifunctional ligands for the Via vasopressin receptor. Eur J Biochem 1993;213:711-719.
36. Ramsay D, Kellett E, McVey M, Rees S, Milligan G: Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. Biochem J 2002;365:429-440.
37. Mercier JF, Salahpour A, Angers S, Breit A, Bouvier M: Quantitative assessment of beta 1- and beta 2-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer. J Biol Chem 2002;277:44925-44931.
38. Vrecl M, Jorgensen R, Pogacnik A, Heding A: Development of a BRET2 screening assay using beta-arrestin 2 mutants. J Biomol Screen 2004;9:322-333.
39. Terrillon S, Barberis C, Bouvier M: Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A 2004;101:1548-1553.
40. Chen Z, Dupre DJ, Le Gouill C, Rola-Pleszczynski M, Stankova J: Agonist-induced internalization of the platelet-activating factor receptor is dependent on arrestins but independent of G-protein activation: role of the C terminus and the (D/N)PXXY motif. J Biol Chem 2002;277:7356-7362.
41. Mueller A, Kelly E, Strange PG: Pathways for internalization and recycling of the chemokine receptor CCR5. Blood 2002;99:785-791.
42. Orsini MJ, Parent JL, Mundell SJ, Benovic JL, Marchese A: Trafficking of the HIV coreceptor CXCR4: role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization. J Biol Chem 1999;274:31076-31086.
43. Tarasova NI, Stauber RH, Michejda CJ: Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4. J Biol Chem 1998;273:15883-15886.
44. Issafras H, Angers S, Bulenger S, Blanpain C, Parmentier M, Labbe-Jullie C, et al: Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem 2002;277:34666-34673.
45. Kraft K, Olbrich H, Majoul I, Mack M, Proudfoot A, Oppermann M: Characterization of sequence determinants within the carboxyl-terminal domain of chemokine receptor CCR5 that regulate signaling and receptor internalization. J Biol Chem 2001;276:34408-34418.
46. Cheng ZJ, Zhao J, Sun Y, Hu W, Wu YL, Cen B, et al: beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem 2000;275:2479-2485.
47. Venkatesan S, Rose JJ, Lodge R, Murphy PM, Foley JF: Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell 2003;14:3305-3324.
48. Venkatesan S, Petrovic A, Locati M, Kim YO, Weissman D, Murphy PM: A membrane-proximal basic domain and cysteine cluster in the C-terminal tail of CCR5 constitute a bipartite motif critical for cell surface expression. J Biol Chem 2001;276:40133-40145.
49. Percherancier Y, Planchenault T, Valenzuela-Fernandez A, Virelizier JL, Arenzana-Seisdedos F, Bachelerie F: Palmitoylation-dependent control of degradation, life span, and membrane expression of the CCR5 receptor. J Biol Chem 2001;276:31936-31944.
50. Blanpain C, Wittamer V, Vanderwinden JM, Boom A, Renneboog B, Lee B, et al: Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways. J Biol Chem 2001;276:23795- 23804.
51. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-377.
52. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
53. Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, et al: Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997;186:1373-1381.
54. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, et al: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci U S A 2001;98:12718-12723.
55. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
56. Ali H, Richardson RM, Tomhave ED, DuBose RA, Haribabu B, Snyderman R: Regulation of stably transfected platelet activating factor receptor in RBL-2H3 cells: role of multiple G proteins and receptor phosphorylation. J Biol Chem 1994;269:24557-24563.
57. Raport CJ, Gosling J, Schweickart VL, Gray PW, Charo IF: Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem 1996;271:17161-17166.
58. Ling K, Wang P, Zhao J, Wu YL, Cheng ZJ, Wu GX, et al: Five-transmembrane domains appear sufficient for a G protein-coupled receptor: functional five-transmembrane domain chemokine receptors. Proc Natl Acad Sci U S A 1999;96:7922-7927.